Ariosa Diagnostics

Ariosa Diagnostics, Inc. is a global molecular diagnostics company committed to improving overall patient care by developing and delivering innovative, affordable, and widely-accessible testing services through its CLIA laboratory. Tests are fully validated to CLIA requirements by rigorous and comprehensive methodologies to ensure healthcare practitioners and patients can be confident in the test’s performance. Ariosa has developed the technologies to perform a directed analysis of cell-free DNA in blood.
Company Growth (employees)
San Jose, US
Size (employees)
125 (est)-3%
Ariosa Diagnostics was founded in 2009 and is headquartered in San Jose, US

Ariosa Diagnostics Office Locations

Ariosa Diagnostics has an office in San Jose
San Jose, US (HQ)
5945 Optical Court

Ariosa Diagnostics Data and Metrics

Summary Metrics

Founding Date


Total Funding

$67.5 m

Latest funding size

$52.7 m

Time since last funding

over 5 years


Ariosa Diagnostics's latest funding round in January 2012 was reported to be $52.7 m. In total, Ariosa Diagnostics has raised $67.5 m

Traffic Overview of Ariosa Diagnostics

Ariosa Diagnostics News and Updates

Diagnostics company LabCorp to buy smaller rival Sequenom

July 27 (Reuters) - Laboratory Corporation of America Holdings said it would buy Sequenom Inc, a maker of non-invasive prenatal tests for reproductive health, for about $371 million, including debt.

UPDATE 2-U.S. Supreme Court refuses to review prenatal test patent dispute

NEW YORK, June 27 (Reuters) - The U.S. Supreme Court on Monday rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for paten…

U.S. Supreme Court weighs review of canceled patent on prenatal test

NEW YORK (Reuters) - Companies, trade groups and universities who fear that many important discoveries may no longer qualify for patents are among a broad coalition urging the U.S. Supreme Court to review the cancellation of a patent on a less risky form of prenatal testing.

Ariosa Diagnostics Company Life and Culture

You may also be interested in